• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Science & Research

  • Print
  • Share
  • E-mail

MAQC Timeline

Red envelope icon for GovdeliveryGet e-mail updates when this information changes.

Microarrays and next-generation sequencing represent core technologies in pharmacogenomics and toxicogenomics; however, before these technologies can successfully and reliably be used in clinical practice and regulatory decision-making, standards and quality measures need to be developed. The MAQC project is helping improve the microarray and next-generation sequencing technologies and foster their proper applications in discovery, development and review of FDA regulated products. Everyone is invited to participate in the MAQC project.

  • February 11, 2005: Phase I of the MAQC project (MAQC-I) on microarray technical performance launched
  • June 5, 2006: MAQC-I manuscripts submitted
  • September 8, 2006: MAQC-I results published in September 2006 issue of Nature Biotechnologydisclaimer icon
  • September 8, 2006: MAQC-I datasets made publicly available
  • September 21, 2006: MAQC-II on predictive models (signatures) launched
  • August 28, 2007: “Pharmacogenomic Data Submissions — Companion Guidance” released
  • December 16-17, 2008: MAQC-III (or SEQC) on next-generation sequencing launched
  • March 2009: MAQC-II manuscripts submitted
  • August 2010: MAQC-II results published in August 2010 issues of Nature Biotechnologydisclaimer icon and Pharmacogenomics Journaldisclaimer icon


Contact Information

Please address questions and suggestions about the MicroArray Quality Control project to Dr. Leming Shi at Leming.Shi@fda.hhs.gov or Dr. Weida Tong at Weida.Tong@fda.hhs.gov or Reagan Kelly at Reagan.Kelly@fda.hhs.gov.


Contact FDA

National Center for Toxicological Research

Food and Drug Administration

3900 NCTR Road

Jefferson, AR 72079